Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(18):1353; doi:10.1093/jnci/djm161
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© Oxford University Press 2007.
The first 10% of the full text of this article appears below.

High-Grade Prostate Cancer, Prostate Volume, and Finasteride

The Prostate Cancer Prevention Trial (PCPT) reported that patients taking finasteride, a 5{alpha}-reductase inhibitor, had a decreased incidence of prostate cancer overall. However, the incidence of high-grade cancer was higher in the finasteride group than the placebo group. One possible explanation for this increase is that finasteride induces high-grade tumors, but several other mechanisms could also explain it.

To investigate whether the increase could be due to finasteride's influence on prostate volume or tumor morphology, Lucia et al. (p. 1375) examined prostate biopsy samples from PCPT participants with high Gleason scores for hormonal effects and pathologic . . . [Full Text of this Article]

Cancer Mortality in the United States by Education and Race

Cancer Yield of Prostate Biopsies Prompted by PSA Screening

Lung Cancer Survival and Functional Polymorphisms in MBL2

Oncolytic Adenovirus Delta-24-RGD and Brain Tumor Stem Cells